Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH

Primary inclusion criteria: * Histologically confirmed diagnosis of melanoma * Progressive disease that is not surgically resectable, or metastatic Stage IV disease * Measurable disease (revised RECIST; Version 1.1) * Serum LDH not more than 1.1 times the upper limit of normal * Eastern Cooperative Oncology Group performance status 0 or 1 * Treatment with 1 prior regimen (including cytotoxic chemotherapy, immunotherapy, radiation therapy, or cytokine, biologic, or vaccine therapy) as first-line treatment for metastatic disease (Administration of interleukin-2 or interferon as adjuvant therapy is allowed and is not to be considered in determining the 1 prior treatment regimen administered as first-line treatment for metastatic disease.) * Adequate bone marrow, hepatic, and renal function, as specified in the protocol * At least 3 weeks and recovery from effects of prior surgery or other therapy with an approved or investigational agent * Ability to swallow an oral solid-dosage form of medication Primary exclusion criteria: * History or presence of brain metastasis or leptomeningeal disease * Primary ocular or mucosal melanoma * Significant medical disease other than cancer * Organ allograft * Presence of neuropathy \> Grade 1 (National Cancer Institute Common Toxicity Criteria \[NCI CTC\]; Version 4.0) * Prior treatment with a taxane or other tubulin-targeted agent (eg, indibulin) other than a vinca alkaloid * Need to continue any regularly-taken medication that is a potent inhibitor or inducer of the CYP3A pathway or P-glycoprotein activity